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Abstract 
 
According to the US Department of Health and Human Services, more than 2 million Americans 
suffer from opioid use disorder (DHHS, 2020).  Opioid maintenance therapy (OMT) for OUD 
has been shown to reduce the rates of inpatient hospitalization and overall opioid-related 
mortality (Quaye & Zhang, 2019).   Buprenorphine is a partial mu receptor agonist and kappa 
receptor antagonist that is used frequently by patients on OMT.  Beginning in 2010 annual 
prescriptions for buprenorphine products have increased dramatically (Lembke, Ottestad, & 
Schmiesing, 2019). 
With the rising level of chronic pain and opioid use nationally, more and more patients 
taking buprenorphine are presenting to the perioperative setting.  The pharmacology of 
buprenorphine presents a unique challenge to the anesthesia provider particularly with regards to 
achieving adequate pain control during and after surgery.  A review of the literature indicates 
that there are no unified guidelines on the perioperative management of buprenorphine.  The 
focus of this paper is to discuss the unique pharmacology of buprenorphine and review the 
current literature on the best perioperative management strategies for patients on buprenorphine.  
The case study included provides an example of one patient’s perioperative experience while on 
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Current Recommendations for the Perioperative Management of Patients on  
Buprenorphine: A Case Study 
 
According to the US Department of Health and Human Services (DHHS), there were 
10.3 million misused prescription opioids in 2018.  Two million people were considered to have 
an opioid use disorder (OUD) and more than 130 people die every day from opioid-related drug 
overdoses.  In 2017 the Department of Health and Human Services declared a public health 
emergency and announced a 5-Point Strategy to Combat the Opioid Crisis.  The five strategies 
include: improving access to treatment and recovery services; promoting the use of overdose-
reversing drugs; strengthening our understanding of the epidemic through better public health 
surveillance; providing support for cutting edge research on pain and addiction; and advancing 
better practices for pain management (DHHS, 2020). 
The epidemic of opioid addiction in the United States is not new.  The fight to tackle the 
addiction problem began as early as 1920.  In 1929 the National Research Council and the 
United States government formed a task force designed to identify non-habit-forming opioids 
(US Committee on Opportunities in Drug Abuse Research, 1996).  The goal was to find a less 
addictive drug that would provide analgesia without affecting the respiratory drive.  Over the 
years many new drugs were developed, but none that met the criteria of the task force committee.  
In the 1950s research began to focus on combination narcotic agonists/antagonists as a possible 
solution and buprenorphine emerged as a promising new drug (Campbell & Lowell, 2012).   
Buprenorphine: A Partial Opioid Agonist 
Buprenorphine is a semisynthetic opioid first developed in 1966 from thebaine, an 
alkaloid compound derived from the poppy flower. It was first used in 1978 as an analgesic to 
treat chronic pain in cancer patients (Davis, Pasternak, & Behm, 2018).  Shortly after it was 
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introduced, clinicians noted that when buprenorphine was administered in higher doses for 
moderate pain, patients received no relief from other opioids administered for breakthrough pain.  
Buprenorphine is a partial mu-receptor agonist and kappa-receptor antagonist with an extremely 
high affinity for these receptors.  The affinity is so high that it effectively blocks other opioids 
from binding to the mu-opioid and kappa-opioid receptors, preventing the patient from 
experiencing the effects of subsequently administered opioids (Bryson, 2014).  For this reason, 
buprenorphine has become a popular choice in patients with OUD because they do not 
experience the euphoria from other administered opioids which effectively discourages their 
opioid abuse.  It was officially approved by the Federal Drug Administration for the treatment of 
opioid addiction in 2002.   
 Buprenorphine is manufactured for the treatment of opioid addiction in many different 
sublingual formulations.  It is marketed as buprenorphine only (Subutex) and in combination 
with naloxone (Suboxone).  It is also available as buccal, intravenous, intramuscular injections,  
and as a transdermal patch.  When taken sublingually the naloxone has little effect but is 
included in the formulation to discourage IV use.  It is 25-50x more potent than morphine and 
has a half-life of about 37 hours due to its slow dissociation from the mu receptors.  The onset of  
action is 30-60 minutes with the SL preparation.  Buprenorphine is metabolized in the liver, has a 
high volume of distribution, and is highly protein bound (Jonan, Kaye, & Urman, 2018).  
Buprenorphine was once thought to be associated with less respiratory depression than full mu-
opioid agonists, however according to a systematic review of 28 randomized controlled trials by 
White et al (2018), this theory has since been disproven.  The studies show that there is no 
difference in analgesia or respiratory depression when compared with morphine.  
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 Transdermal buprenorphine was first used in Europe in 1981 and is now being used for 
the treatment of chronic pain, neuropathic pain, and cancer pain.  The patch is available in 5, 10, 
and 20 mcg/hour patches called Butrans that provide 7 days of therapy (Vadivelu, Mitra, Kaye, 
& Urman, 2014).  Very low doses are needed to provide analgesia when compared with the 
doses needed for the treatment of opioid addiction. 
 
A Case Study 
  
The case involves a 36-year-old female, weighing 68 kg, who presented to the emergency 
department with fatigue, confusion, nausea, and vomiting.  The patient complained of painful 
hands and bluish discoloration on scattered fingers was noted.  She had significant dental decay.  
Her history included current pack per day smoker and significant intravenous drug abuse.  The 
patient’s prescribed medications included buprenorphine 12 mg daily, clonazepam 1 mg daily, 
and gabapentin 300 mg TID.  Her labs on admission were as follows:  Na 134 mEq/l,  
K 2.9 mEq/l, CO2 17 mm Hg, Anion gap 19 mEq/L, BUN 43 mg/dl, Cr 2.82 mg/dl,  
Lactate 1.7 mmol/L, WBC 15,100 u/L, Hgb 10.7 g/dl, Hct 30.7%, and Platelets 114,000 mm3.  
CT scans of head and abdomen were both negative.  The patient was hypotensive in the ED  
despite two liters of fluid resuscitation and required norepinephrine for blood pressure support.  
She was given the likely diagnosis of endocarditis given the lesions on her hands and feet which 
were consistent with Janeway lesions.  Vancomycin and Zosyn were initiated per pharmacy 
dosing and the patient was admitted to the ICU.  A TTE was negative for vegetations.   
The following day a TEE showed a 1.7 cm vegetation on the mitral valve and an 
estimated ejection fraction of 69%.  Blood cultures tested positive for MSSA and the patient 
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required two vasopressors for BP support.  She was started on a continuous Nafcillin infusion per 
infectious disease.   
After being off buprenorphine for 2 days, the patient was restarted on buprenorphine 12 
mg daily and was transferred out of the ICU to the floor.  Several days later the patient went to 
the OR to have her teeth completely removed.  The patient’s scheduled acetaminophen and 
gabapentin were held prior to surgery and the patient was in 10 out of 10 pain post dental 
extractions.  Oral lidocaine was ordered.  The following day the patient was started on 
oxycodone 15 mg every 4 hours for pain control and the buprenorphine dose was changed to 8 
mg daily.  The patient expressed frustration with inadequate pain control, stating that she did 
okay with 15 mg oxycodone and 12 mg buprenorphine while recovering from a c-section 
previously.  She requested to increase the dose of oxycodone and maintain her usual dose of 12 
mg of buprenorphine.  The patient was not interested in taking methadone.  She was continued 
on buprenorphine 8 mg daily and oxycodone 10 mg every 4 hours. 
A week later the patient was taken to the OR for repair of her mitral valve.  Intraoperative 
medications included; versed 2 mg, fentanyl 350 mcg, ketamine 100 mg in divided doses.  She 
was transferred to the CTICU immediately post operation and remained intubated until later that  
afternoon.  An infusion of ketamine 0.1 mg/kg/hr was initiated along with a hydromorphone 
PCA without a continuous rate.  Her buprenorphine was continued at 8 mg daily.  Tylenol 1000 
mg every 6 hours and gabapentin 400 mg TID were also initiated for pain control.   
On post-operative day one the patient reported feeling generally well with complaints of 
intermittent incisional pain.  The patient appeared to be sleeping comfortably.  Her ketamine 
infusion was discontinued on post-op day 2.  The hydromorphone PCA continued with the 
buprenorphine and gabapentin.  The patient reported satisfactory pain relief, but not optimal.  On 
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post-op day 4 the patient reported increased pain after the hydromorphone PCA was 
discontinued.  The buprenorphine continued at the same dose of 8 mg daily.  By post-op day 5 
the patient was satisfied with her pain control and was taking PO hydromorphone every 3-4 
hours as well as Tylenol and gabapentin.   Her buprenorphine was maintained at 8 mg daily 
throughout her hospital stay. 
This case study illustrates that the patient’s pain was controlled relatively well throughout 
the perioperative period while continuing a moderate dose of buprenorphine and that by post-op 
day 5 satisfactory pain relief was achieved on oral medications alone.  Additional opioids given 
appeared to be effective in the management of her pain as evidenced by the fact that upon 
discontinuation of the hydromorphone PCA the patient reported an increase in pain. 
Literature Review 
Research Supporting Continuation of Buprenorphine  
 A retrospective cohort study was published in 2013 by MacIntyre, Russell, Usher, 
Gaughwin, & Huxtable.  The study compared pain relief and opioid requirements in the first 24 
hours after surgery in 22 patients on buprenorphine and 29 patients on methadone who were 
prescribed patient controlled analgesia (PCA).  The study concluded that there were no 
significant differences in pain scores between the patient groups overall, but that the patients  
taking buprenorphine who did not take their usual dose on the day after surgery used 
significantly more PCA opioid than those who had taken their dose.  It was found that most of 
those patients had not taken their usual dose of buprenorphine on the morning of their surgery   
either.  Similarly, a 9-year observational study by Vilkens et al, 2017, concluded that there was 
no meaningful difference in the opioid requirements for women on buprenorphine versus women 
on methadone who underwent a cesarean section.  This study aimed to find out if patients being 
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maintained on buprenorphine achieve adequate pain control similar to those being treated with 
methadone during the perioperative period.  The continuation of methadone during the 
perioperative period is considered standard practice, whereas the continuation of buprenorphine 
remains controversial.  The study did point out however that the women on buprenorphine 
utilized a significant more amount of ketorolac and this may have contributed to the equivalent 
use of postoperative opioids between the two groups. These studies suggest that the continuation 
of buprenorphine before and after surgery does not increase opioid requirements.   
A case study by Leighton & Crock (2017) involving 4 obstetric patients on 
buprenorphine reports good-to-excellent pain management.  The first patient was a healthy 22 -
year- old parturient whose only medication was buprenorphine/naloxone (Suboxone) 8mg/2mg 
twice daily.  She had spinal anesthesia and was comfortable during cesarean delivery.  Post 
operatively buprenorphine was continued.  Pain control was maintained with an epidural infusion 
of bupivacaine, scheduled doses of 30 mg ketorolac IV every 6 hours for 4 doses and then 
scheduled 800 mg ibuprofen orally every 8 hours.  At 48 hours post-op the epidural was 
removed, and the patient’s pain scores were never higher than 1/10.   
The second patient described was a healthy 23 -year -old who took buprenorphine 4 mg 
three times daily.  She also had a combined spinal/epidural for pain management and was 
comfortable during cesarean delivery.  Buprenorphine was continued at the preoperative dose.  
This patient also received scheduled doses of ketorolac 30 mg every 6 hours, and then ibuprofen 
800 mg every 8 hours.  The epidural infusion was discontinued on post-operative day 2 and the 
patient was discharged on ibuprofen.  Pain scores were never higher than 3-4/10 during the first 
24 hours and for a brief time 10/10 due to a pump failure but this was quickly resolved with an 
epidural bolus of 10 ml bupivacaine 0.25%.   
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The third patient was a 34-year-old patient who originally denied substance abuse but 
later was found to test positive for buprenorphine during the urine drug screen.  Patient was 
comfortable during delivery with spinal anesthesia but refused an epidural for post-op pain 
control.  Three hours after surgery the patient rated her pain as an intolerable 10/10.  A 
hydromorphone PCA was initiated as well as scheduled doses of ketorolac 30 mg every 6 hours 
for 4 doses and then ibuprofen 800 mg every 8 hours.  After the initiation of the PCA, the highest 
pain score recorded was 5/10.  On post-op day two the PCA was discontinued with no increase in 
pain and the patient was discharged on ibuprofen.   
The last patient was a healthy 25-year-old whose only medication was buprenorphine 4 
mg daily.  The patient was comfortable during delivery with the help of spinal anesthesia.  Three 
hours post-op she rated her pain as 4-5/10.  She was given ketorolac 30 mg and her pain 
decreased to 1-2/10.  The patient was continued on her buprenorphine and ketorolac.  She was 
discharged on acetaminophen and diclofenac with pain scores never higher than 2/10.  In each of 
these cases the patients all reached a point within 48-72 hours after surgery in which they only 
required buprenorphine and nonsteroidal anti-inflammatory agents for pain control.  Ketamine 
and dexmedetomidine have also been successfully added to multimodal analgesia in patients on 
buprenorphine.  Although they did not use either drug in these cases the authors encourage other 
clinicians to consider doing so.     
Mercadente et al (2006) studied 29 cancer patients who were treated with transdermal 
buprenorphine and were given IV morphine for breakthrough pain.  Ninety-two percent of the 
episodes were treated successfully. Success was defined as a 33% reduction in pain intensity 
within 15 minutes.  Eighty-three percent of the episodes had a more than 50% reduction in pain.   
Beltrutti et al, (2002) also described two cancer patients who experienced sustained pain relief 
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after receiving intrathecal morphine and intravenous buprenorphine.  A randomized, double-
blind, placebo-controlled study compared 45 ASA II and III patients undergoing hysterectomy 
with general anesthesia.  Patients were given either intrathecal morphine or IV buprenorphine 
(1.3 microgram/kg), or both.  The patients who had received both medications concurrently 
resulted in lower pain scores suggesting that buprenorphine (at analgesic doses) and morphine 
interact synergistically to reduce pain more effectively than when each medication was 
administered alone, (Quaye & Zhang, 2019).  
In a case study by Kornfeld & Manfredi (2010) five patients were maintained on 
buprenorphine perioperatively.  Adequate pain control was achieved in all patients by oral or IV 
opioid agonists and, in all but one patient, regional anesthesia.  Quaye and Zhang’s (2019) 
review of the literature involving obstetric patients concluded that buprenorphine can 
successfully be continued throughout the delivery and post-partum period by combining a 
multimodal analgesic approach.   
Research Supporting Discontinuation of Buprenorphine 
Khelemsky, Schauer, and Loo (2015) present a case study of a woman on buprenorphine 
undergoing cervical spine surgery.  A 44-year-old woman presented for emergency anterior 
cervical corpectomy and fusion for the treatment of a pathological fracture with spinal cord 
compression.  Among others, her medications included Suboxone 8mg/2mg for the treatment of 
opioid abuse.  Due to the use of neuromonitoring for the surgery, a total IV anesthetic was 
utilized.  Muscle relaxation was avoided.  Propofol 150 mcg/kg/min and remifentanil 0.4 
mcg/kg/min infusions were initiated after an uneventful induction and intubation.  An hour into 
the procedure the patient began to move her legs and over-breathe the ventilator.  The propofol 
infusion was increased to 200 mcg/kg/min and a 2 mg versed bolus was given along with a  
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100 mcg remifentanil bolus.  A motionless surgical field was obtained only after the 
administration of a ketamine bolus of 50 mg and an infusion at 100 mg/hr.  The patient remained 
intubated following the case.  Five days after the initial surgery, the patient returned to the 
operating room for arthrodesis with posterior segmental instrumentation.  She was not given any  
buprenorphine during those five days and was maintained on short-acting opioids.  After an 
uneventful induction and intubation, a propofol infusion of 125 mcg/kg/min and remifentanil 
infusion of 0.2 mcg/kg/min was started.  No ketamine was required for the procedure and the 
patient was extubated at the end of the case.  This case is limited in that it describes only a single 
patient but suggests that the presence of buprenorphine hindered the maintenance of a motionless 
surgical field.  Surgery could only continue after the administration of ketamine.  
Bryson (2014) concludes that standard opioid-based analgesic techniques are often not 
sufficient to achieve adequate pain control in patients maintained on buprenorphine who present 
for surgery.  Because of buprenorphine’s unique pharmacology, patients on this drug require 
substantially higher doses of opioids or alternative non-opioid based techniques in order to 
achieve an adequate level of pain control in the perioperative setting.  Ideally buprenorphine  
should be discontinued 72 hours before surgery and then restarted once the patient no longer has 
acute pain requiring opioid analgesics.  McCormick et al (2013) reported a case of a 50-year-old 
patient who presented with compartment syndrome.  Pain control was difficult to achieve in this 
patient who was maintained on buprenorphine for chronic pain and opioid dependence.  
Successful pain management only occurred 48 hours after admission and involved stopping the 
buprenorphine and administering escalating doses of hydromorphone.  Twelve milligrams of 
intravenous hydromorphone had little effect on this patient’s initial pain scores.   
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 Huang, Katznelson, de Perrot, and Clark (2014) report a 47-year-old woman on 
buprenorphine for chronic pain who underwent open window thoracoscopy for pulmonary  
aspergillosis.  Her postoperative pain was unbearable despite high doses of intravenous 
hydromorphone.  After buprenorphine was discontinued, her pain improved and her opioid 
requirement was reduced.  Another similar report describes a patient taking buprenorphine who 
underwent a posterior spinal fusion and had uncontrolled postoperative pain.  His pain scores 
improved only after discontinuing the buprenorphine and being taken to the ICU for 
dexmedetomidine and high dose opioid therapy (Brummett, Trividi, Dubovoy, & Berland 2009).  
Gilmore, Saccheti, & Cortese (2012) describe a case report of a 22-year-old male who 
presented to the emergency department with a comminuted distal radial and ulnar fracture caused 
by a work-related injury.  His pain was ineffectively treated despite 10 mg of morphine and a 1 
microgram/kg bolus dose of remifentanil with an infusion of 1.7 microgram/kg/min.  When it 
was found that the patient was on buprenorphine, the opioid analgesics were discontinued, and 
the pain was successfully relieved with a Bier block. 
Discussion 
Positron emission tomographic (PET) scans have been used to study the effects of 
buprenorphine at the receptor level.  The data found that at buprenorphine maintenance doses of 
16 and 32 mg SL tablets, the brain mu-opioid receptor availability is reduced by 80 and 84% 
respectively, whereas the reduction is only 41% with the 2 mg dose (Macintyre, Russell, Usher, 
Gaughwin, & Huxtable, 2013).  Studies of mu-opioid receptor availability through PET scans 
lead to a better understanding of the dose range where buprenorphine can have an additive effect 
when used with other mu receptor agonists.  Zubieta et al, (2000) also found that buprenorphine 
induced dose-dependent reductions in mu-opioid receptor availability.  A 36-50% reduction at a 
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2 mg dose and 79-95% at a 16 mg dose was found in multiple brain regions including the 
prefrontal cortex, anterior cingulate, caudate, putamen, thalamus, amygdala, and cerebellum.  
High dose buprenorphine produced near maximal mu-opioid receptor occupation.  At the 32 mg 
dose, buprenorphine blocked 94-98% of receptors in most regions throughout the brain.  These 
studies show that at moderate doses of buprenorphine (8-12 mg daily), there is up to 20% mu-
opioid receptor site availability.   
One case study by Martin, Deljou, Weingarten, Schroeder, and Sprung, (2019) involving 
32 patients on buprenorphine was entirely inconclusive.  The opioid requirements of patients 
who continued sublingual buprenorphine (SL-BUP) until the day of surgery and those who 
discontinued SL-BUP preoperatively were compared.  There were many limitations including the 
small sample size and its retrospective design.  The small group of patients underwent various 
types of procedures and received various types of anesthesia ranging from regional only, general 
only, or both regional and general.  Therefore, the authors have stated that best practices for 
patients receiving SL-BUP cannot be determined based on the findings of this study alone.  The 
opioid requirements of patients being treated with SL-BUP were high in both groups regardless 
of the type of procedure, type of anesthesia and whether or not they had continued or 
discontinued their buprenorphine.   
While an exhausting review of the literature proves that there is no clear consensus on the 
recommendations for patients on chronic buprenorphine therapy, the evidence suggests 
continuation of the buprenorphine at moderate doses throughout the perioperative period may 
lead to the best patient outcomes.   There are no randomized controlled trials available and the 
articles reviewed are limited in that they are based on pharmacologic principles, numerous case 
studies, and expert opinions.   While there are several case reports suggesting that pain control 
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was achieved only after the discontinuation of buprenorphine, there is also much evidence to 
support that acute pain control is very challenging in patients on buprenorphine irrespective of 
continuation.  A case report of a 37-year-old woman with chronic pelvic pain on 8 mg 
buprenorphine had two similar gynecological procedures 6 months apart.  For the first case the 
patient maintained her buprenorphine dose and struggled with postoperative pain control.  The 
decision was made for the second procedure to discontinue the buprenorphine 5 days prior to 
surgery.  The patient’s post-operative pain was equally difficult to control (Chern, Isserman, 
Chen, & Liu, 2012).  This study illustrates the challenge that patients taking buprenorphine 
present regardless of continuation versus discontinuation of the medication. 
Acute pain management in patients taking buprenorphine for OUD is complex, 
multifactorial, and influenced by more than the pharmacologic properties associated with 
concomitant buprenorphine and full opioid agonist administration (Quaye & Zhang, 2019).   
 
Recommendations 
An editorial by Lembke, Ottestad, and Schemiesing (2019) recommends that patients on 
buprenorphine therapy continue the medication throughout the perioperative period.  For those 
on higher doses (more than 12 mg daily) scheduled to undergo painful procedures such as total 
joints or open abdominal surgery, a lower dose protocol is recommended.  The authors outline  
four reasons why discontinuing buprenorphine prior to surgery introduce unnecessary risk for 
patients with opioid use disorder.  First, discontinuing buprenorphine is complex and may even 
delay surgery to allow adequate time to taper.  This will require more clinic visits and care 
coordination between multiple providers, burdening the patient with additional instructions and 
tasks.  Second, the process of re-starting buprenorphine after surgery is likely to be painful and 
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medically destabilizing for patients because it forces them into a state of active withdrawal 
before buprenorphine can be re-started.  Third, this process is logistically complicated and labor- 
intensive, especially when multiple providers are involved.  Lastly, patients on buprenorphine for 
opioid use disorder are at increased risk for relapse to opioid misuse and accidental overdose 
when buprenorphine is discontinued.  The recommendation to taper patients down to 12 mg of 
buprenorphine when possible is based on receptor occupancy theories and clinical experience.   
A study by Quaye and Zhang (2019) reviews the literature on the perioperative 
management of buprenorphine.  While the article presents evidence on both sides of the 
conundrum, it concludes that maintaining buprenorphine perioperatively does not lead to 
worsened outcomes and that patients can achieve adequate pain control from mu-opioid agonists 
while continuing to take buprenorphine.  The article highlights several studies showing that 
buprenorphine can be given with full mu-opioid agonists to achieve pain relief.  Quaye and 
Zhang (2019) conclude that it is unnecessary and maybe even harmful to completely stop 
buprenorphine maintenance before surgery.  This practice has been shown to increase the risk of 
opioid withdrawal, relapse, and the exacerbation of chronic pain.   
In the past, popular opinion has been to discontinue buprenorphine several days prior to 
surgery due to the unique pharmacological properties of buprenorphine and the perceived 
difficulty in treating postoperative acute pain.  More recently there is evidence that the clinical 
implications of its pharmacology may not be as insurmountable as once believed and that  
effective pain control is possible when patients are continued on buprenorphine perioperatively 
(Quaye & Zhang, 2019). The exact dosing is still questionable and further studies would be  
beneficial to determine an optimal dose, meanwhile a moderate dose (8-12 mg) is considered to 
be appropriate for continuation in most situations.  The nature of the surgery along with the 
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anticipated level of postoperative pain should be considered when making a plan for these 
patients and possible intensive care monitoring should be anticipated.  Not only is there not any 
high-level evidence that maintaining buprenorphine leads to worsened outcomes, but abrupt 
discontinuation is associated with a high risk of relapse in patients with OUD.    
The Acute Pain Services (APS) at the University of Michigan created a protocol  
(Figure 1 & 2) with the assistance of physicians specializing in buprenorphine management.  
Figure 1 details the considerations for elective surgery and Figure 2 deals with urgent/emergent 
surgeries.  Each of these protocols provides detailed instructions to either continue or discontinue 
the buprenorphine based on the anticipated level of post-operative pain and opioid requirements.  
The protocol encourages collaboration with the patient’s primary buprenorphine provider and 
strongly recommends a multimodal approach including regional anesthesia when possible 




PERIOPERATIVE RECOMMENDATIONS FOR BUPRENORPHINE 17 
 
Figure 1.  Acute Pain Services (APS) Protocol for elective procedures at the University of 
Michigan.  Reprinted from: University of Michigan Health Systems. (2017) Management 
of sublingual buprenorphine (suboxone and subutex) in the acute perioperative setting.  
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Figure 2.  Acute Pain Services (APS) Protocol for elective procedures at the University of 
Michigan.  Reprinted from: University of Michigan Health Systems. (2017) Management 
of sublingual buprenorphine (suboxone and subutex) in the acute perioperative setting.  
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The University of Michigan APS protocol is not without opposition. According to Alford, 
2014 the idea of discontinuing buprenorphine 5 days prior to surgery is based on the theoretical 
concern of pharmacological principles and has never been properly evaluated.  This practice 
risks causing a disruption in the patient’s recovery from opioid addiction by stopping 
buprenorphine during a high anxiety preoperative period.  Alford also debates the certainty of the 
ceiling effect of buprenorphine stating that there is no published data indicating an analgesic 
ceiling in humans.  The work by Alford confirms that a clear consensus among providers 
regarding the management of patients on buprenorphine during the perioperative setting is 
lacking.   
 Prior to January 2018, the practice at Massachusetts General Hospital was to 
withhold buprenorphine 72 hours before surgery and supplement with opioid agonists to prevent 
withdrawal.  This practice met several challenges including patients who were fearful of stopping 
buprenorphine due to concerns of relapse and providers who were concerned with the legal 
aspects of providing opioids to patients with a history of OUD.  Due to these issues and the lack 
of high-level evidence, a multidisciplinary clinician group was formed to help guide practice.  
The group consisted of twenty clinicians with experience in the following disciplines: 
perioperative pain management, chronic pain management, addiction medicine, psychology, 
psychiatry, and anesthesia.  This algorithm also takes into consideration the anticipated pain 
level of the specific surgery, similar to Figures 1 & 2.  Instead of a plan to discontinue 
buprenorphine all together, a dose of less than 16 mg is recommended up until the day of surgery 
and then a reduced dose of 8 mg during the postoperative period to be given along with other 
opioids as needed until surgical pain subsides. The group reached a revised consensus resulting 
in the algorithm shown in Figure 3.   
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Figure 3.  Algorithm for perioperative management of buprenorphine at Mass General.  
Reprinted from:  Perioperative Management of Buprenorphine: Solving the Conundrum, 
by Quaye and Zhang, 2019 in Pain Medicine; 20 (7). p 1395-1408.  Doi: 
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While it has been established by multiple case studies that there is no clear consensus on 
the perioperative management of these patients, there are some recommendations that are agreed 
upon in all the studies.  These recommendations include proper preoperative planning involving 
a pain management specialist and mental health professional when possible.  Thorough  
preoperative education is crucial in setting realistic expectations of the likelihood for increased 
post-operative pain.  Another recommendation is the use of multimodal analgesia to include 
regional techniques when appropriate.  Multi modal analgesia simultaneously targets pain 
pathways at different sites using different mechanisms and is associated with superior pain relief 
and decreased opioid consumption.  This includes the use of NSAIDS, gabapentinoids, ketamine, 
alpha-2 agonists, lidocaine, and magnesium (Anderson et al, 2016). 
There may be some instances where discontinuation of the buprenorphine completely 
may be appropriate.  All patients should be treated on an individual basis taking into account all 
aspects of the patient’s history and nature of the upcoming surgery.  Optimal management begins 
in the preoperative period and is on the basis of a thorough patient assessment and development 
of a plan of care tailored to the individual and the surgical procedure involved, with follow up 
assessments and adjustments as needed (Chou et al, 2016). 
Conclusion 
 The pharmacokinetic and pharmacodynamic properties of buprenorphine make it 
especially appealing for the treatment of chronic pain and addiction.  Pain management during 
the perioperative period is complex, especially in patients who are taking buprenorphine.  There 
are many different angles to consider when planning for these patients.   
More studies are needed, specifically randomized controlled trials to determine the best 
perioperative management of patients taking buprenorphine.  Meanwhile, the recommendation 
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can be made to continue buprenorphine perioperatively at a moderate dose (8-12 mg) in most 
cases where postoperative pain is not expected to be severe.  Formulation of a plan during the 
preoperative period and education of the patient regarding the plan and postoperative 
expectations is vital to success.  Lastly, and perhaps most important, is to implement a 
multimodal approach for treating postoperative pain targeting as many different receptors as 
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